+1 Recommend
0 collections
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      Anakinra Therapy for Non-cancer Inflammatory Diseases


      Read this article at

          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.


          Interleukin-1 (IL-1) is the prototypical inflammatory cytokine: two distinct ligands (IL-1α and IL-1β) bind the IL-1 type 1 receptor (IL-1R1) and induce a myriad of secondary inflammatory mediators, including prostaglandins, cytokines, and chemokines. IL-1α is constitutively present in endothelial and epithelial cells, whereas IL-1β is inducible in myeloid cells and released following cleavage by caspase-1. Over the past 30 years, IL-1-mediated inflammation has been established in a broad spectrum of diseases, ranging from rare autoinflammatory diseases to common conditions such as gout and rheumatoid arthritis (RA), type 2 diabetes, atherosclerosis, and acute myocardial infarction. Blocking IL-1 entered the clinical arena with anakinra, the recombinant form of the naturally occurring IL-1 receptor antagonist (IL-1Ra); IL-1Ra prevents the binding of IL-1α as well as IL-1β to IL-1R1. Quenching IL-1-mediated inflammation prevents the detrimental consequences of tissue damage and organ dysfunction. Although anakinra is presently approved for the treatment of RA and cryopyrin-associated periodic syndromes, off-label use of anakinra far exceeds its approved indications. Dosing of 100 mg of anakinra subcutaneously provides clinically evident benefits within days and for some diseases, anakinra has been used daily for over 12 years. Compared to other biologics, anakinra has an unparalleled record of safety: opportunistic infections, particularly Mycobacterium tuberculosis, are rare even in populations at risk for reactivation of latent infections. Because of this excellent safety profile and relative short duration of action, anakinra can also be used as a diagnostic tool for undefined diseases mediated by IL-1. Although anakinra is presently in clinical trials to treat cancer, this review focuses on anakinra treatment of acute as well as chronic inflammatory diseases.

          Related collections

          Most cited references222

          • Record: found
          • Abstract: found
          • Article: not found

          NLRP3 inflamasomes are required for atherogenesis and activated by cholesterol crystals that form early in disease

          The inflammatory nature of atherosclerosis is well established but the agent(s) that incite inflammation in the artery wall remain largely unknown. Germ-free animals are susceptible to atherosclerosis, suggesting that endogenous substances initiate the inflammation1. Mature atherosclerotic lesions contain macroscopic deposits of cholesterol crystals in the necrotic core but their appearance late in atherogenesis had been thought to disqualify them as primary inflammatory stimuli. However, using a novel microscopic technique, we revealed that minute cholesterol crystals are present in early diet-induced atherosclerotic lesions and that their appearance coincides with the first appearance of inflammatory cells. Other crystalline substances can induce inflammation by stimulating the caspase-1-activating NLRP3 inflammasome2,3, which results in cleavage and secretion of IL-1 family cytokines. Here, we demonstrate that cholesterol crystals also activate the NLRP3 inflammasome in phagocytes in vitro in a process that involves phago-lysosomal damage. Similarly, when injected intraperitoneally, cholesterol crystals induce acute inflammation, which is impaired in mice deficient in components of the NLRP3 inflammasome, cathepsin B, cathepsin L, or IL-1 molecules. Moreover, when low-density lipoprotein receptor (LDLR) deficient mice were reconstituted with NLRP3-, ASC-, or IL-1α/β-deficient bone marrow and fed a high cholesterol diet, they had markedly reduced early atherosclerosis and inflammasome-dependent IL-18 levels. Our results demonstrate that crystalline cholesterol acts as an endogenous danger signal and its deposition in arteries or elsewhere is an early cause rather than a late consequence of inflammation. These findings provide new insights into the pathogenesis of atherosclerosis and point to new potential molecular targets for the therapy of this disease. Cholesterol, an indispensable lipid in vertebrates, is effectively insoluble in aqueous environments and elaborate molecular mechanisms have evolved that regulate cholesterol synthesis and its transport in fluids4. Cholesterol crystals are recognized as a hallmark of atherosclerotic lesions5 and their appearance helps in the histopathological classification of advanced atherosclerotic lesions6. However, crystalline cholesterol is soluble in the organic solvents used in histology, so that the presence of large crystals is identifiable but only indirectly as so-called cholesterol crystal clefts, which delineate the space that was occupied before sample preparation. The large cholesterol crystal clefts in atherosclerotic plaques were typically only observed in advanced lesions and, therefore, crystal deposition was thought to arise late in this disease. However, given that atherosclerosis is intimately linked to cholesterol levels, we were interested to determine when and where cholesterol crystals first appear during atherogenesis. We fed atherosclerosis-prone Apo-E-deficient mice a high cholesterol diet to induce atherosclerosis7,8 and used a combination of laser reflection and fluorescence confocal microscopy3 to identify crystalline materials and immune cells. Many small crystals appeared as early as two weeks after the start of atherogenic diet within small accumulations of subendothelial immune cells in very early atherosclerotic sinus lesions (Fig. 1a, b and Supplementary Fig. 1, 2). The reflective material was identified as being mostly cholesterol crystals by fillipin staining (not shown). Crystal deposition and immune cell recruitment increased steadily with diet feeding and the appearance of crystals correlated with that of macrophages (r2=0.99, p<0.001) (Fig. 1a-d). Cholesterol crystals were not only detected in necrotic cores but also in subendothelial areas that were rich in immune cells. Confocal imaging revealed crystals to localize both inside and outside of cells (Fig. 1b), whereas in corresponding H&E stained sections that were treated with organic solvents during the staining process cholesterol crystal clefts were visible only after 8 weeks of diet and smaller crystals remained invisible (Fig. 1a). As expected, we failed to detect macrophages or accumulation of crystals in the aortic sinus sections in mice on a regular chow diet (Fig. 1a, b; bottom panel). Additional observations in human advanced atherosclerotic lesions showed that areas rich in immune cells also contained smaller crystals inside and outside of cells in addition to the larger crystals that would leave cholesterol crystal clefts in standard histology (Supplementary Fig. 3, 4). These studies establish that crystals emerge at the earliest time points of diet-induced atherogenesis together with the appearance of immune cells in the subendothelial space. Various crystals that are linked to tissue inflammation, as well as pore-forming toxins or extracellular ATP, can activate IL-1 family cytokines via triggering of NLRP39. Of note, NLRP3 inflammasome formation requires a priming step that can be provided by pattern recognition or cytokine receptors that activate NF-κB. Cellular priming leads to induction of pro-forms of IL-1 family cytokines and NLRP3 itself, a step, which is required for NRLP3 activation at least in vitro 10. To test whether cholesterol crystals could activate the release of IL-1β, we incubated LPS-primed human PBMCs with cholesterol crystals. Cholesterol crystals induced a robust, dose-responsive release of cleaved IL-1β in a caspase-1 dependent manner (Fig. 2a, b). Of note, cholesterol crystals added to unprimed cells did not release IL-1β into the supernatant indicating the absence of any contaminants that would be sufficient for priming of cells (Fig. 2a)10. IL-1 cytokines are processed by caspase-1, which can be activated by various inflammasomes9. Since the NLRP3 inflammasome has been reported to recognize a variety of crystals, we next stimulated macrophages from mice deficient in NLRP3 inflammasome components. Cholesterol crystals induced caspase-1 cleavage and IL-1β release in wild-type but not NLRP3- or ASC-deficient macrophages (Fig. 2c, d). Transfected dsDNA (dAdT), a control activator that induces the AIM-2 inflammasome11, activated caspase-1 and induced IL-1β release in an ASC-dependent yet NLRP3-independent manner, as expected (Fig. 2c, d). In addition, mouse macrophages also produced cleaved IL-18, another IL-1 family member that is processed by inflammasomes (Fig. 2e). We also found that chemically pure synthetic cholesterol crystals activated the NLRP3 inflammasome providing further evidence that cholesterol crystals themselves rather than contaminating molecules were the biologically active material (Supplementary Fig. 5a). Notably, priming of cells for NLRP3 activation could be achieved by other pro-inflammatory substances such as cell wall components of Gram-positive bacteria (Supplementary Fig. 5b). Moreover, minimally modified LDL also primes cells for NLRP3 activation (Supplementary Fig. 5c)12. Together, these data establish that crystalline cholesterol leads to NLRP3 inflammasome activation in human and mouse immune cells. Several hypotheses regarding the molecular mechanisms of NLRP3 inflammasome activation have been formulated3,13. To further elucidate the mechanisms involved in cholesterol crystal recognition, we pharmacologically inhibited phagocytosis with cytochalasin D or lantriculin A and found that these agents inhibited NLRP3 inflammasome activation by crystals (Fig. 3 and Supplementary Fig. 6 a, c, d). In contrast, these inhibitors did not block the activation of the NLRP3 inflammasome by the pore-forming toxin nigericin or the AIM2 activator dAdT (Fig. 3a and Supplementary Fig. 6a, c, d). To follow the fate of the internalized particles, we performed combined confocal reflection and fluorescence microscopy in macrophages incubated with cholesterol crystals. This analysis revealed that cholesterol crystals induced profound swelling in a fraction of cells (Fig. 3b) as observed for other aggregated materials3,14. Phago-lysosomal membranes contain lipid raft components15, which allowed us to stain the surface of cells with the raft marker choleratoxin B labeled with one fluorescent color and additionally label internal phago-lysosomal membranes after cell permeabilization with differently fluorescing choleratoxin B. Indeed, in macrophages that had previously ingested cholesterol crystals this staining revealed that some cholesterol crystals lacked phago-lysosomal membranes and resided in the cytosol of a fraction of cells, thus indirectly indicating crystal-induced phago-lysosomal membrane rupture (Fig. 3c). This finding was further supported by crystal-induced translocation of soluble lysosomal markers into the cytosol (see below). Additionally, in mouse macrophages cholesterol crystals dose-responsively led to a loss of lysosomal acridine orange fluorescence further confirming lysosomal disruption (Fig. 3d). These studies suggest that cholesterol crystals induced lysosomal damage in macrophages leads to the translocation of phago-lysosomal content into the cytosol. In further experiments we found that the inhibition of lysosomal acidification or cathepsin activity blocked the ability of cholesterol crystals to induce IL-1β secretion (Fig. 3e). Likewise, analysis of cells from mice deficient in single cathepsins (B or L) also showed that cholesterol crystals led to a diminished IL-1β release when compared to wild-type cells. However, the dependency of cholesterol crystal-induced IL-1β release on single cathepsins was less pronounced at higher doses suggesting functional redundancy of cathepsin B and L or potentially additional proteases (Fig. 3f). Together, these experiments suggest that cholesterol crystals induce translocation of lysosomal proteolytic contents, which can be sensed by the NLRP3 inflammasome by as yet undefined mechanisms. It has previously been demonstrated that oxidized LDL, a major lipid species deposited in vessels, has the potential to damage lysosomal membranes16. We found that macrophages incubated with oxidized LDL internalized this material and nucleated crystals in large, swollen, phago-lysosomal compartments (Fig. 3g); and in some cells these compartments ruptured with translocation of the fluorescent marker dye into the cytosol (Fig. 3g, arrows). A time course analysis revealed that small crystals appeared as early as one hour after incubation with oxidized LDL (not shown) and larger crystals were visible after longer incubation times (Fig. 3h). It is likely that cholesterol crystals form due to the activity of acid cholesterol ester hydolases, which transform cholesteryl esters supplied by oxidized LDL into free cholesterol. As indicated above, minimally modified LDL can prime cells for the NLRP3 inflammasome activation (Supplementary Fig. 5c). Recent evidence suggests that this priming proceeds via the activation of a TLR4/6 homodimer and CD3612. This, together with the propensity of minimally modified LDL to form crystals and to rupture lysosomal membranes, suggests that these LDL species could be sufficient to provide both signals 1 and 2 needed to activate IL-1β release from cells. Indeed, after 24 h incubation we observed spontaneous release of IL-1β in the absence of further NLRP3 inflammasome stimulation (Fig. 3i). In murine atherosclerotic lesions we identified not only macrophages and dendritic cells but also neutrophils accumulated within the intima space (see Supplementary Fig. 2). IL-1β plays a key role in the recruitment of neutrophils, and the IL-1-dependent intraperitoneal accumulation of neutrophils has frequently been used as an in vivo assay for inflammasome activation and IL-1 production2,17,18. Using this acute inflammation model we found that cholesterol crystals induced a robust induction of neutrophil influx into the peritoneum (Fig. 4a). Neutrophil influx into the peritoneum after cholesterol crystal deposition was markedly reduced in mice lacking IL-1 or the IL-1 receptor (IL-1R), indicating that IL-1 production is indeed induced and essential for cholesterol crystal-induced inflammation in vivo. Moreover, mice lacking NLRP3 inflammasome components or cathepsins B or L also recruited significantly fewer neutrophils into the peritoneum after cholesterol crystal injection than wild-type mice. However, the reduction in neutrophilic influx observed after cholesterol crystal deposition was more pronounced in mice lacking IL-1 related genes than in mice lacking NLRP3 inflammasome related genes (Fig. 4a), presumably because of the contribution of IL-1α signaling and/or caspase-1-independent processing of IL-1β19 in vivo. In any case, these data confirm that cholesterol crystals trigger NLRP3 inflammasome-dependent IL-1 production in vivo. To test whether the NLRP3 inflammasome is involved in the chronic inflammation that underlies atherogenesis in vessel walls, we tested whether the absence of NLRP3, ASC or IL-1 cytokines might modulate atherosclerosis development in LDLR-deficient mice20, a model for familial hypercholesterolemia. We reconstituted lethally irradiated LDLR-deficient mice with bone marrow from wild-type or NLRP3-,ASC- or IL1α/β-deficient mice and subjected these mice to 8 weeks of a high cholesterol diet. In these radiation bone marrow chimeras, the LDLR-deficiency radioresistant parenchyma causes the animals to become hypercholesterolemic when placed on a high fat diet, while their bone-marrow derived macrophages and other leukocytes lack the NLRP3-inflammasome or IL-1 pathway components needed to respond to cholesterol crystals. We found that the different groups of mice had similar levels of elevated blood cholesterol (not shown). However, mice reconstituted with NLRP3-, ASC-, or IL-1α/b-deficient bone marrow showed significantly lower plasma IL-18 levels, an IL-1 family cytokine whose secretion is dependent on inflammasomes and a biomarker known to be elevated in atherosclerosis21 (Fig. 4b). Additionally, and most importantly, mice whose bone marrow-derived cells lacked NLRP3 inflammasome components or IL-1 cytokines were markedly resistant to developing atherosclerosis (Fig. 4c, d). The lesional area in the aortas of these mice was reduced on average by 69% compared to chimeric LDLR-deficient mice that had wild-type bone marrow. These data demonstrate that activation of the NLRP3 inflammasome by bone marrow derived cells is a major contributor to diet-induced atherosclerosis in mice. The molecules that incite inflammation in atherosclerotic lesions have presented a long-standing puzzle. While the lesions are absolutely dependent on cholesterol, this abundant, naturally occurring molecule has been viewed as inert. Here, we show that the crystalline form of cholesterol can induce inflammation. The magnitude of the inflammatory response and the mechanism of NRLP3 activation appear identical to that of crystalline uric acid, silica and asbestos2,3,13. All these crystals are known to provoke clinically important inflammation as seen in gout, silicosis and asbestosis, respectively. The chronic inflammation in gout, silicosis and asbestosis is thought to derive from the inability of cells to destroy the ingested aggregates leading to successive rounds of apoptosis and reingestion of the crystalline material22. In the same way, immune cells cannot degrade cholesterol and depend, instead, on exporting the cholesterol to HDL particles, which carry the cholesterol to the liver for disposal. The success of this or any cellular mechanism in clearing crystals may thus depend on the availability of HDL. Low blood HDL levels are among the most prominent risk factors for atherosclerotic disease23, and pharmacologic means for increasing HDL are being actively pursued as treatments. Even though cholesterol cannot be degraded by peripheral cells it may be transformed to cholesteryl ester by the cellular enzyme, acylcoenzyme A:cholesterol acyltransferase (ACAT). Cholesteryl esters form droplets rather than crystals and are considered a storage form of cholesterol4. On the assumption that reduced cholesterol storage would be beneficial for reducing atherosclerosis, ACAT inhibitors were tested in large clinical trials. Studies with two such inhibitors showed not a decrease but an increase in the size of the coronary atheroma24,25. This apparent paradox may be reconciled by our findings that the crystalline form of cholesterol, which would be expected to be increased after inhibition of ACAT, may be key in driving arterial inflammation. Indeed, murine studies of ACAT-deficiency show enhanced atherogenesis with abundant cholesterol crystals26. Based on our findings, therapeutic strategies that would reduce cholesterol crystals or block the inflammasome pathway would be predicted to have clinical benefit by reducing the initiation or progression of atherosclerosis. In this context our findings also point to novel molecular targets for the development of therapeutics to treat this disease. Methods summary Mice Mice were kindly provided as follows: NLRP3−/− and ASC−/− (Millenium Pharmaceuticals); Caspase-1−/− (R. Flavell, Yale University, New Haven, CT). Cathepsin B−/− (T. Reinheckel, Albert-Ludwigs-University, Freiburg, Germany), Cathepsin L−/− (H. Ploegh, Whitehead Institute, Cambridge, MA), IL-1α−/− IL-1β−/−, IL-1α−/−β−/− (Yoichiro Iwakura, The Institute of Medical Sciences, The University of Tokyo, Tokyo, Japan). B6-129 (mixed background), C57BL/6, IL-1R−/−, ApoE−/− and LDLR−/− mice were purchased from The Jackson Laboratories. Animal experiments were approved by the UMass and Massachusetts General Hospital Animal Care and Use Committees. Cell culture media and reagents Immortalized macrophage cell lines and bone-marrow derived cells were cultured as described3 and primed with 10 ng/ml LPS for 2h prior to addition of inflammasome stimuli. Inhibitors were added 30 min prior to stimuli. Crystals and dAdT were applied 6h, ATP (5 mM) and nigericin (10 µM) 1h before supernatant was collected. Poly(dA:dT) was transfected using Lipofectamine 2000 (Invitrogen). Human PBMCs were freshly isolated by Ficoll-Hypaque gradient centrifugation, grown in RPMI medium (Invitrogen), 10% FBS (Atlas Biologicals) 10µg/ml ciprofloxacin (Celgro) at 2 × 105 cells per 96 well and primed with 50 pg/ml LPS for 2 hours before addition of inflammasome stimuli. Supernatants were assessed for IL-1β by ELISA and western blot. Neutrophil recruitment to peritoneal cavity Mice were intraperitoneally injected with 2 mg of cholesterol crystals in 200 µl PBS or PBS alone. After 15 hours, peritoneal lavage cells were stained with fluorescently conjugated mAbs against Ly-6G (Becton Dickinson, clone 1A8) and 7/4 (Serotec) in the presence of mAb 2.4G2 (FcgRIIB/III receptor blocker). The absolute number of neutrophil (Ly-6G+ 7/4+) was determined by flow cytometry. Methods Reagents Bafilomycin A1, cytochalasin D and zYVAD-fmk were from Calbiochem. ATP, acridine orange and poly(dA:dT) sodium salt were form Sigma-Aldrich and ultra-pure LPS was purchased from Invivogen. Nigericin, Hoechst dye, DQ ovalbumin and fluorescent choleratoxin B were purchased from Invitrogen. MSU crystals were prepared as described17. Cholesterol crystal preparation Tissue-culture grade or synthetic cholesterol was purchased from Sigma, solubilized in hot acetone and crystallized by cooling. After 6 cycles of recrystallizations, the final crystallization was performed in the presence of 10% endotoxin-free water to obtain hydrated cholesterol crystals. Cholesterol crystals were analyzed for purity by electron impact GC/MS and thin layer chromatography using silica gel and hexane-ethyl acetate (80:20) solvent. Crystal size was varied using a microtube tissue grinder. Fluorescent cholesterol was prepared by addition of the DiD or DiI dyes (Invitrogen) in PBS. ELISA and Western Blot ELISA measurements of IL-1β (Becton Dickinson) and IL-18 (MBL International) were made according to the manufacturer’s directions. Experiments for caspase-1 Western blot analysis were performed in serum-free DMEM medium. After stimulations, cells were lysed by the addition of a 10X lysis buffer (10% NP-40 in TBS and protease inhibitors), and post-nuclear lysates were separated on 4–20% reducing SDS-PAGE. Anti murine caspase-1 pAb was kindly provided by P. Vandenabeele (University of Ghent, The Netherlands). Anti-human cleaved IL-1β (Cell Signaling) from human PBMCs was analyzed in serum-free supernatants as above without cell lysis. Confocal microscopy ApoE−/− mice that were maintained in a pathogen-free facility were fed a Western-type diet (Teklad Adjusted Calories 88137; 21% fat (wt/wt), 0.15% cholesterol (wt/wt) and 19.5% casein (wt/wt); no sodium cholate) starting at 8 weeks of age and continued for 2, 4, 8 or 12 weeks (three mice in each group). Mice were euthanized and hearts were collected as described27. Hearts were serially sectioned at the origins of the aortic valve leaflets, and every third section (5 µm) was stained with hematoxylin and eosin and imaged by light microscopy. Adjacent sections were fixed in 4% paraformaldehyde, blocked and permeabilized (10% goat serum / 0.5% saponin in PBS) and stained with fluorescent primary antibodies against macrophages (MoMa-2, Serotec), DCs (CD11c, Becton Dickinson) or neutrophils (anti-Neutrophil, Serotec) for 1 h at 37 °C for imaging by confocal microscopy. Human atherosclerotic lesions were obtained directly after autopsy, serially sectioned at 2- to 3-mm intervals and frozen sections (5 mm) were prepared as above. Parallel sections were stained with Masson’s trichrome stain. Tissues were prepared for microscopy as above. Macrophages were stained with anti-CD68 (Serotec), smooth muscle cells were visualized with fluorescent phalloidin (Invitrogen). Human and mouse samples were counterstained with Hoechst dye to visualize nuclei. The atherosclerotic lesions were imaged on a Leica SP2 AOBS confocal microscope where immunofluoroscence staining was visualized by standard confocal techniques and crystals were visualized utilizing laser reflection using enhanced transmittance of the acousto-optical beam splitter as described3. Of note, laser reflection and fluorescence emission occurs at the same confocal plane in this setup. The mean lesion area, amount of crystal deposition and monocyte marker presence was quantified from three digitally captured sections per mouse (Photoshop CS4 Extended). For the quantification of crystal mass and macrophages present, the sum of positive pixels (laser reflection or fluorescence, respectively) was determined and the area calculated from the pixel size. Confocal microscopy of mouse macrophages was performed as described3. DQ ovalbumin only fluoresces upon proteolytic processing and marks phagolysosomal compartments in macrophages. Acridine orange lysosomal damage assay This assay was performed by flow cytometry as described3. Bone marrow transplantation and atherosclerosis model Eight weeks-old female LDLR−/− mice were lethally irradiated (11 Gy). Bone marrow was prepared from femurs and tibias of C57BL/6, NLRP3−/−, ASC−/− and IL-1α−/−b−/− donor mice and T cells were depleted using complement (Pel-Freez Biologicals) and anti-Thy1 mAB (M5/49.4.1, ATCC). Irradiated recipient mice were reconstituted with 3.5 × 106 bone marrow cells administered into the tail vein. After 4 weeks, mice were fed with a Western-type diet (Teklad Adjusted Calories 88137; 21% fat [wt/wt], 0.15% cholesterol [wt/wt] and 19.5% casein [wt/wt]; no sodium cholate) for 8 weeks. Mice were euthanized and intracardially perfused with formalin. Hearts were embedded in OTC (Richard-Allen Scientific, Kalamazoo, MI) medium, frozen, and serially sectioned through the aorta from the origins of the aortic valve leaflets and every single section (10 µm) throughout the aortic sinus (800 µm) was collected. Quantification of average lesion area was done from 12 stained with hematoxylin eosin or Giemsa per mouse by two independent investigators with virtually identical results. Serum cholesterol levels were determined by enzymatic assay (Wako Diagnostics), and serum IL-18 was measured by SearchLight protein array technology (Aushon Biosystems, Billerica, MA). Statistical analyses The significance of differences between groups was evaluated by one–way analysis of variance (ANOVA) with Dunnett’s post- comparison test for multiple groups to control group, or by Student’s t test for 2 groups. R squared was calculated from the Pearson correlation coefficient. Analyses were done using Prism (GraphPad Software, Inc.). Supplementary Material 1 2 3
            • Record: found
            • Abstract: found
            • Article: not found

            The inflammasomes: guardians of the body.

            The innate immune system relies on its capacity to rapidly detect invading pathogenic microbes as foreign and to eliminate them. The discovery of Toll-like receptors (TLRs) provided a class of membrane receptors that sense extracellular microbes and trigger antipathogen signaling cascades. More recently, intracellular microbial sensors have been identified, including NOD-like receptors (NLRs). Some of the NLRs also sense nonmicrobial danger signals and form large cytoplasmic complexes called inflammasomes that link the sensing of microbial products and metabolic stress to the proteolytic activation of the proinflammatory cytokines IL-1beta and IL-18. The NALP3 inflammasome has been associated with several autoinflammatory conditions including gout. Likewise, the NALP3 inflammasome is a crucial element in the adjuvant effect of aluminum and can direct a humoral adaptive immune response. In this review, we discuss the role of NLRs, and in particular the inflammasomes, in the recognition of microbial and danger components and the role they play in health and disease.
              • Record: found
              • Abstract: found
              • Article: not found


              Silicosis is a fibrotic lung disease caused by inhalation of free crystalline silicon dioxide or silica. Occupational exposure to respirable crystalline silica dust particles occurs in many industries. Phagocytosis of crystalline silica in the lung causes lysosomal damage, activating the NALP3 inflammasome and triggering the inflammatory cascade with subsequent fibrosis. Impairment of lung function increases with disease progression, even after the patient is no longer exposed. Diagnosis of silicosis needs carefully documented records of occupational exposure and radiological features, with exclusion of other competing diagnoses. Mycobacterial diseases, airway obstruction, and lung cancer are associated with silica dust exposure. As yet, no curative treatment exists, but comprehensive management strategies help to improve quality of life and slow deterioration. Further efforts are needed for recognition and control of silica hazards, especially in developing countries. Copyright © 2012 Elsevier Ltd. All rights reserved.

                Author and article information

                Front Pharmacol
                Front Pharmacol
                Front. Pharmacol.
                Frontiers in Pharmacology
                Frontiers Media S.A.
                06 November 2018
                : 9
                [1] 1Unit of Immunology, Rheumatology, Allergy and Rare Diseases, San Raffaele Hospital, Vita-Salute San Raffaele University , Milan, Italy
                [2] 2Department of Medicine, Radboud University Medical Center , Nijmegen, Netherlands
                [3] 3Department of Medicine, University of Colorado Denver , Denver, CO, United States
                Author notes

                Edited by: Paolo Sfriso, Università degli Studi di Padova, Italy

                Reviewed by: Leonardo Punzi, Università degli Studi di Padova, Italy; Sergey V. Ryzhov, Maine Medical Center, United States; Francecso Cinetto, Università degli Studi di Padova, Italy

                *Correspondence: Giulio Cavalli, cavalli.giulio@ 123456gmail.com Charles A. Dinarello, cdinare333@ 123456aol.com

                This article was submitted to Inflammation Pharmacology, a section of the journal Frontiers in Pharmacology

                Copyright © 2018 Cavalli and Dinarello.

                This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

                Page count
                Figures: 2, Tables: 3, Equations: 0, References: 283, Pages: 21, Words: 0

                Pharmacology & Pharmaceutical medicine
                interleukin 1,il-1β,il-1α,rheumatology,inflammation
                Pharmacology & Pharmaceutical medicine
                interleukin 1, il-1β, il-1α, rheumatology, inflammation


                Comment on this article